检测血清可溶性白细胞介素─2受体水平在食管癌放疗前后的临床意义  

Soluble Interleukin-2 Receptor in Esophageal Carcinoma Patients before and after Radiotherapy

作　　者：刘小平[1] 安怀伦[1] 姜缨[1] 张哲舫[1] 赵洪涛 

机构地区：[1]西安医科大学附属第一医院肿瘤科

出　　处：《中国肿瘤临床》1995年第8期561-563,共3页Chinese Journal of Clinical Oncology

摘　　要：用双抗体夹心酶联免疫吸附试验检测了５７例食管癌患者放疗前及放疗后血清可溶性白细胞介素─２受体（ＳＩＬ─２Ｒ）水平。结果显示：食管癌患者放疗前血清ＳＩＬ─２Ｒ水平显著高于正常对照，且和食管病变长度密切相关。放疗后血清ＳＩＬ─２Ｒ水平较放疗前显著降低，且放疗后血清ＳＩＬ─２Ｒ水平与正常对照组比较无明显差异。放疗后血清ＳＩＬ─２Ｒ水平降低程度在完全缓解（ＣＲ）和部分缓解（ＰＲ）病人之间无明显差异。食管癌患者血清ＳＩＬ─２Ｒ水平与其肿瘤的消长密切相关，可以作为疗效和判断预后的一个监测指标。The serum levels of soluble interleukin-2 receptor (sIL-2R) before and after radiotherapy in 57 esophageal carcinoma patients were determined. Thedata showed that serum sIL-2R levels in patients were significantly higher than that of healthy controls(P<0.001), and that the serum levels correlated with the length of esophagus involved. The serum levels of sIL-2R were remarkably reduced at the end of radiotherapy(p<0.001). It is suggested that monitoring serum sIL-2R levels has clinical and prognostic significance in patients with esophageal carcinoma and that prospective studies are indicated.

关 键 词：白细胞介素-2 受体 食管肿瘤 放射疗法 

分 类 号：R730.55[医药卫生—肿瘤]